Technology
Health
Biotechnology

ADMA Biologics

$3.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-1.76%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ADMA Biologics and other stocks, options, ETFs, and crypto commission-free!

About

ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. Read More The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Employees
318
Headquarters
Ramsey, New Jersey
Founded
2006
Market Cap
184.02M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
281.72K
High Today
$4.13
Low Today
$3.87
Open Price
$4.04
Volume
171.27K
52 Week High
$6.96
52 Week Low
$2.08

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Manufacturing
Pharmaceutical
2013 IPO

News

Markets InsiderMar 13

ADMA Biologics Reports Full Year 2018 Financial Results

RAMSEY, N.J. and BOCA RATON, Fla., March 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases, today announced its financial results for the year ended December 31, 2018, and provided an update on its op...

333
MarketBeatMar 7

Stock Price, News, & Analysis for ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of ...

78
StreetInsiderMar 4

Form 8-K ADMA BIOLOGICS, INC. For: Mar 04

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2019 ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 465 State Route 17, Ramsey, New Jersey 07446 (Address of princ...

8

Earnings

-$0.59
-$0.47
-$0.36
-$0.24
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.35 per share
Actual
-$0.39 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.